BR112022022235A2 - Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r - Google Patents
Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4rInfo
- Publication number
- BR112022022235A2 BR112022022235A2 BR112022022235A BR112022022235A BR112022022235A2 BR 112022022235 A2 BR112022022235 A2 BR 112022022235A2 BR 112022022235 A BR112022022235 A BR 112022022235A BR 112022022235 A BR112022022235 A BR 112022022235A BR 112022022235 A2 BR112022022235 A2 BR 112022022235A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- eosinophilic esophagitis
- inhibitors
- administration
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029085P | 2020-05-22 | 2020-05-22 | |
| US202063066705P | 2020-08-17 | 2020-08-17 | |
| US202063071264P | 2020-08-27 | 2020-08-27 | |
| US202063088147P | 2020-10-06 | 2020-10-06 | |
| US202063121088P | 2020-12-03 | 2020-12-03 | |
| US202163144939P | 2021-02-02 | 2021-02-02 | |
| EP21315068 | 2021-04-21 | ||
| PCT/US2021/033693 WO2021237110A1 (en) | 2020-05-22 | 2021-05-21 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022235A2 true BR112022022235A2 (pt) | 2023-03-28 |
Family
ID=76444669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022235A BR112022022235A2 (pt) | 2020-05-22 | 2021-05-21 | Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250154267A2 (enExample) |
| EP (1) | EP4153300A1 (enExample) |
| JP (1) | JP2023527775A (enExample) |
| KR (1) | KR20230015965A (enExample) |
| CN (1) | CN115768516A (enExample) |
| AU (1) | AU2021277398A1 (enExample) |
| BR (1) | BR112022022235A2 (enExample) |
| CA (1) | CA3174431A1 (enExample) |
| IL (1) | IL298257A (enExample) |
| MX (1) | MX2022014440A (enExample) |
| WO (1) | WO2021237110A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| RU2704999C2 (ru) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Способ лечения кожной инфекции путем введения антагониста il-4r |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| EP4442323A3 (en) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| CN112153982A (zh) | 2018-05-13 | 2020-12-29 | 瑞泽恩制药公司 | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 |
| MX2021011141A (es) | 2019-03-21 | 2022-01-19 | Regeneron Pharma | Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia. |
| AU2020326713A1 (en) | 2019-08-05 | 2022-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| EP4010001A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| WO2024011251A1 (en) | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| TW202502820A (zh) | 2023-03-27 | 2025-01-16 | 美商再生元醫藥公司 | 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法 |
| WO2025221247A1 (en) * | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2005047331A2 (en) | 2003-11-07 | 2005-05-26 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| WO2008054606A2 (en) | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| KR101867279B1 (ko) | 2010-10-06 | 2018-06-15 | 리제너론 파아마슈티컬스, 인크. | 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형 |
| TR201802772T4 (tr) * | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TWI682781B (zh) * | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2017189805A1 (en) * | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| TWI777515B (zh) * | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| IL315556A (en) * | 2017-08-04 | 2024-11-01 | Regeneron Pharma | Methods for treating active eosinophilic esophagitis |
| US11053309B2 (en) * | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| RU2020128551A (ru) * | 2018-02-21 | 2022-03-21 | АДЭР ФАРМАСЬЮТИКАЛЗ ЮЭс, Л.П. | Способы ведения эозинофильного эзофагита |
| WO2019240288A1 (ja) * | 2018-06-14 | 2019-12-19 | 味の素株式会社 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
-
2021
- 2021-05-21 US US17/327,504 patent/US20250154267A2/en active Pending
- 2021-05-21 IL IL298257A patent/IL298257A/en unknown
- 2021-05-21 AU AU2021277398A patent/AU2021277398A1/en active Pending
- 2021-05-21 KR KR1020227045054A patent/KR20230015965A/ko active Pending
- 2021-05-21 EP EP21732754.3A patent/EP4153300A1/en active Pending
- 2021-05-21 CA CA3174431A patent/CA3174431A1/en active Pending
- 2021-05-21 MX MX2022014440A patent/MX2022014440A/es unknown
- 2021-05-21 WO PCT/US2021/033693 patent/WO2021237110A1/en not_active Ceased
- 2021-05-21 CN CN202180036330.4A patent/CN115768516A/zh active Pending
- 2021-05-21 BR BR112022022235A patent/BR112022022235A2/pt unknown
- 2021-05-21 JP JP2022571133A patent/JP2023527775A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115768516A (zh) | 2023-03-07 |
| KR20230015965A (ko) | 2023-01-31 |
| WO2021237110A1 (en) | 2021-11-25 |
| CA3174431A1 (en) | 2021-11-25 |
| IL298257A (en) | 2023-01-01 |
| US20210363264A1 (en) | 2021-11-25 |
| US20250154267A2 (en) | 2025-05-15 |
| EP4153300A1 (en) | 2023-03-29 |
| JP2023527775A (ja) | 2023-06-30 |
| AU2021277398A1 (en) | 2023-02-02 |
| MX2022014440A (es) | 2023-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022022235A2 (pt) | Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r | |
| BR112022000377A2 (pt) | Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r | |
| BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
| BR112014008764A8 (pt) | Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide | |
| BR112023004020A2 (pt) | Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r | |
| BR112021018627A2 (pt) | Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| BR112022021962A2 (pt) | Imidazopiridazinas como moduladores de il-17 | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| CY1115046T1 (el) | Καινουργια sirnas και μεθοδοι χρησης αυτων | |
| BR112015003590A8 (pt) | Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r | |
| BR112023000675A2 (pt) | Terapia de combinação para tratamento de crescimento celular anormal | |
| BR112022000581A2 (pt) | Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r | |
| Keeshin et al. | Use of prazosin for pediatric PTSD-associated nightmares and sleep disturbances: a retrospective chart review | |
| NO20092905L (no) | Doseringsregime for COMT-ihibitorer | |
| BR112021021195A2 (pt) | Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33 | |
| BR112018017228A2 (pt) | composições e métodos para regeneração do músculo usando prostaglandina e2 | |
| MX2024014467A (es) | Métodos de tratamiento del cáncer con un inhibidor de mtor | |
| MX2024001189A (es) | Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r. | |
| BR112018072263A2 (pt) | métodos de tratamento de doenças nas quais atividade de il-13 é prejudicial usando anti-anticorpos anti-il-13 | |
| MX2021014170A (es) | Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas. | |
| MX2022006176A (es) | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. | |
| BR112022007721A2 (pt) | Método para o tratamento da demência | |
| BR112021006223A2 (pt) | regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |